{"id":"W1505282125","doi":"10.1002/art.38973","title":"Effect of Certolizumab Pegol Over Ninety‐Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial","year":2014,"lang":"en","type":"article","venue":"Arthritis & Rheumatology","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; AstraZeneca (Canada)","funders":"UCB Pharma; Celltrion; Genentech; Celgene; Chugai Pharmaceutical; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; Biogen","keywords":"BASDAI; Medicine; Certolizumab pegol; BASFI; Ankylosing spondylitis; Placebo; Internal medicine; Physical therapy; Randomized controlled trial; Dosing; Rheumatoid arthritis; Etanercept","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002009958,0.0009568987,0.001976828,0.0002869493,0.000375063,0.0009749714,0.0006530016,0.001336358,0.003114338],"category_scores_gemma":[0.001656263,0.0004273778,0.001475672,0.0003414713,0.0006948079,0.0006753503,0.000293574,0.002057801,0.0007000383],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004371463,"about_ca_system_score_gemma":0.0007915884,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004520032,"about_ca_topic_score_gemma":0.0006688072,"domain_scores_codex":[0.9993138,0.0003665616,0.00006156299,0.000109548,0.0000623954,0.00008602389],"domain_scores_gemma":[0.9989216,0.0002862022,0.0003308218,0.0000784571,0.00006994156,0.0003130047],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9575979,0.00580363,0.001098116,0.0008291985,0.001196607,0.00005510108,0.00007018707,0.0003733978,0.003165159,0.00005538684,0.0008110016,0.02894442],"study_design_scores_gemma":[0.930262,0.06465851,0.003437701,0.00004272356,0.0003765252,0.00005803078,0.00001973262,0.000258719,0.0003045607,0.00005310754,0.0005157701,0.00001271184],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9872594,0.008064668,0.0005767802,0.0005105048,0.0002757164,0.001418908,0.0006746097,0.0001367908,0.001082467],"genre_scores_gemma":[0.9902513,0.003424278,0.001155836,0.0007903373,0.0002319658,0.002242165,0.0007888125,0.00001735599,0.001097982],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003114338,"threshold_uncertainty_score":0.01062977,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.004222579586209002,"score_gpt":0.24623893835316,"score_spread":0.242016358766951,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}